About Eutilex
Eutilex is a publicly listed company based in Seoul (South Korea) founded in 2015 by Byoung S Kwon. T cell-based therapeutics and antibodies are developed for cancer treatment. It operates on a HealthTech model. Eutilex has raised $18 million across 1 funding round from investors including Kolon Investments. Its chief executive, as recorded, is Byoung S Kwon. Eutilex offers products and services including Antibody Therapy, T Cell Therapy, and CAR-T Cell Therapy. Its focus areas include Biotechnology and Immunotherapy. Its legal entity is Eutilex Co., Ltd.
Company details
Eutilex is focused on the development of breakthrough immunotherapies targeting incurable and intractable diseases. Solutions are built on core technologies including antibody therapy, T cell therapy, and CAR-T cell therapy. The company operates in the biotechnology sector, aiming to provide new treatment pathways through continuous research and development. Based in Seoul, South Korea, Eutilex is committed to advancing immune-based therapeutic solutions for global health challenges.
- Headquarters Seoul, South Korea
- Founders Byoung S Kwon
- Stage Public
- SectorsHealthcare
- Phone•••• ••••
- Website eutilex.com
- Legal Name Eutilex Co., Ltd.
- Annual Revenue$7.13 M (USD)8.06as on Dec 31, 2025
- Net Profit-$16.56 M (USD)17.98as on Dec 31, 2025
- EBITDA-$10.73 M (USD)31.33as on Dec 31, 2025
- Total Equity Funding$18M (USD)
in 1 rounds
- Latest Funding Round$18M (USD), Series A
Dec 2016
- Investors
Products & Services of Eutilex
Eutilex offers a comprehensive portfolio of products and services, including Antibody Therapy, T Cell Therapy, and CAR-T Cell Therapy.
Innovative antibody therapies are developed for incurable diseases.
T cell therapies are created for immune treatment solutions.
CAR-T therapies are designed for advanced cancer treatment.
Funding Insights of Eutilex
Eutilex has successfully raised a total of $18M through 1 strategic funding round. The most recent funding activity was a Series A round of $18 million completed in December 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $18M
- Total Rounds 1
- Last Round Series A — $18M
- First Round $18M
(Dec 2016)
- Investors Count 1
All 1 funding rounds of Eutilex with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2016 | $18M | Series A | – | – |
1 investors in total: 1 institutional.
Investors in Eutilex
Eutilex has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Kolon Investments.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital and private equity are invested in various sectors. | koloninvest.com | Seoul, South Korea |
Investor details for Eutilex
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Eutilex
1 people are tracked at Eutilex (1 in leadership).
| Name | Role | Group |
|---|---|---|
Byoung S Kwon | Founder & CEO | Leadership |
Complete people profiles for Eutilex
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Eutilex
Eutilex is a publicly listed company on the KRX with ticker symbol 263050 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date24 Dec 2018
- Listed onKRX: 263050
- Listed entityEutilex Co., Ltd.
- Exchange sectorHealth technology
- ISINKR7263050007
- Share price959.00 KRW (+29.95% on the day) · 2026-02-19
- Market capitalisation35,320,813,164.00 KRW
- EPS (diluted, trailing year)-637.97 KRW
- Volume (last session)9,848,152
- Analyst consensusNo rating
Financials of Eutilex
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 10.29B KRW | -23.92B KRW | -15.49B KRW |
| 2024 | 9.53B KRW | -29.17B KRW | -22.56B KRW |
| 2023 | 131.7M KRW | -27.72B KRW | -25.96B KRW |
| 2022 | 215.7M KRW | -33.43B KRW | -32.82B KRW |
| 2021 | 73.5M KRW | -29.26B KRW | -30.30B KRW |
Detailed financial statements for Eutilex
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Eutilex
3 dated milestones of Eutilex across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Eutilex is founded.
- Funding First funding round of $18.0M.
- IPO Lists on the stock exchange (IPO).
Web traffic of Eutilex
The website of Eutilex (eutilex.com) receives about 3.5K visits a month.
- Monthly visits3.5K
▲ 15.8% vs previous month
Websites whose visitors overlap most with Eutilex. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| biotimes.co.kr | 100% | #456,742 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Eutilex
Complete news archive for Eutilex
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Eutilex
Eutilex was founded in 2015 and raised its 1st funding round 1 year after it was founded.
Eutilex is headquartered in Seoul, South Korea.
Byoung S Kwon is the CEO of Eutilex, as recorded in our data. They have also founded this company.
Eutilex is a funded company, having raised a total of $18M across 1 funding round to date. The company's 1st funding round was a Series A of $18M, raised on Dec 2016.
Annual revenue of Eutilex is $7.13M as on Dec 31, 2025.
Eutilex is focused on the development of breakthrough immunotherapies targeting incurable and intractable diseases. Solutions are built on core technologies including antibody therapy, T cell therapy, and CAR-T cell therapy. The company operates in the biotechnology sector, aiming to provide new treatment pathways through continuous research and development. Based in Seoul, South Korea, Eutilex is committed to advancing immune-based therapeutic solutions for global health challenges.
Eutilex offers Antibody Therapy, T Cell Therapy, and CAR-T Cell Therapy.
Yes, Eutilex is publicly traded on KRX under the ticker symbol 263050.
Eutilex has 1 investor. Key investors include Kolon Investments.
Eutilex operates through Eutilex Co., Ltd..